Applying Real Time Release Testing to Powder Processing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Applying Real Time Release Testing to Powder Processing
How to adapt a real time release approach to powder processing during drug-product manufacturing.


Pharmaceutical Technology
Volume 35, Issue 2

RTRT and continuous manufacturing are examples of initiatives that have been catalytic to better material and process understanding. Both depend on a thorough understanding of material properties, beyond the tradition specification of particle-size distribution and tapped density, for example. However, concurrently, the process must be well understood to ensure that the risk of perturbations can be assessed and that the settings, which have traditionally been fixed by regulation, can be modified to accommodate variation in incoming materials and still achieve output material that satisfies the quality attributes.

Advances in measurement technologies and a broadening mindset (helped by the process analytical technology and QbD initiatives) are driving material and process understanding. There are now GMP suites for continuous manufacturing of tablets that rely heavily on PAT and that function with real-time, closed-loop feedback on parameters, such as size, moisture content, and blend uniformity.

For this reason, RTRT has become much more of a reality in the past couple of years. However, there are many material properties that are still not measured routinely at-line or on-line, even though they can influence final product quality. For example, if particle shape is not being monitored, but particle size is and the shape changes, then the powder will perform differently in the press, causing the tablet properties (e.g., weight, hardness, dissolution, stability) to be affected. Yet, the process and quality system may not have accounted for this effect because the material going into the press was conforming to the inadequate specification of particle size.

RTRT is the future for efficient, safe, and competitive pharmaceutical manufacturing. It relies, however, on capturing more information about the materials being processed and the equipment and configuration employed during manufacturing. A closer relationship between formulators, process developers, and plant operators is essential. In addition, the extensive knowledge that exists in manufacturing, such as which products compress well and which are always capping, can be fed back to development to provide the design space necessary for optimal manufacturing and high product quality.

Be sure to check out the additional features related to this article on analytics and on industry and regulatory expectations

Tim Freeman is director of operations at Freeman Technology in the United Kingdom.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here